GlassScriptPhysician profile
Ashlee Robinson
NPI 1518133859
$2,385.03
in general payments reported to CMS, 2019-2025
21 companies · $809 in 2025
The $809 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.18 · 2021: $69.46 · 2022: $211 · 2023: $484 · 2024: $788 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,080.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $412.77 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $313.35 | 2024-2025 | Fanapt, Hetlioz |
| Novo Nordisk INC | $272.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $253.63 | 2022-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $199.04 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $166.04 | 2023-2025 | Rexulti |
| Abbvie INC. | $142.16 | 2021-2025 | Ubrelvy |
| Axsome Therapeutics, INC. | $132.26 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $131.97 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Ironshore Pharmaceuticals INC. | $70.49 | 2022-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $47.62 | 2025 | Jornay Pm |
| Medtronic, INC. | $33.53 | 2025 | Endurant Iis |
| Merck Sharp & Dohme LLC | $31.70 | 2023-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Mylan Specialty L.P. | $30.26 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $28.88 | 2024 | Farxiga |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $28.51 | 2023-2025 | Ingrezza |
| Biogen, INC. | $26.56 | 2025 | Zurzuvae |
| Alkermes, INC. | $19.67 | 2024 | Aristada, Lybalvi |
| Corcept Therapeutics | $15.81 | 2024 | Korlym |
| Glaxosmithkline, LLC. | $14.76 | 2023 | Shingrix, Arexvy |
| Idorsia Pharmaceuticals US INC | $13.75 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlee Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.